

08-27-03

1644

EXPRESS MAIL LABEL NO.: **EV333998993US** Date: August 25, 2003**RESPONSE TO  
RESTRICTION  
REQUIREMENT**

Address to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Attorney Docket No.	SMAR-012
Confirmation No.	4208
First Named Inventor	TUDAN, CHRISTOPHER R.
Application Number	09/835,107
Filing Date	April 12, 2001
Group Art Unit	1647
Examiner Name	BUNNER, BRIDGET E.
Title:	"CXCR4 AGONIST TREATMENT OF HEMAPOIETIC CELLS"

Sir:

This is a response to the Office communication dated July 25, 2003 regarding the Restriction Requirement.

Applicants elect the following species for examination:

- species *ff*: SDF-1 $\alpha$ ;
- species *cc*: peptide spacer sequence linking the N-terminal sequence to the C-terminal sequence;
- species *dd*: an internal cyclic amide bridge formed between a carboxylic acid side chain on a first amino acid residue and an amine side chain on a first amino acid residue and an amine side chain on a second amino acid residue.

Applicant submits that all of the claims are in condition for allowance, which action is requested. If the Examiner finds that a telephone conference would expedite the prosecution of this application, please telephone the undersigned at the number provided.

RECEIVED


AUG 29 2003

TECH CENTER 1600/2900

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number SMAR-012.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: August 25, 2003

By:   
Pamela J. Sherwood  
Registration No. 36,677  
for  
Bret Field  
Registration No. 37,620

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231